vs
Aclarion, Inc.（ACON）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Aclarion, Inc.的15221.7倍（$281.3M vs $18.5K）。Guardant Health, Inc.净利率更高（-45.7% vs -10223.7%，领先10178.1%）。Aclarion, Inc.同比增速更快（80.6% vs 39.4%）。过去两年Aclarion, Inc.的营收复合增速更高（35.2% vs 29.2%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
ACON vs GH — 直观对比
营收规模更大
GH
是对方的15221.7倍
$18.5K
营收增速更快
ACON
高出41.2%
39.4%
净利率更高
GH
高出10178.1%
-10223.7%
两年增速更快
ACON
近两年复合增速
29.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $281.3M |
| 净利润 | $-1.9M | $-128.5M |
| 毛利率 | 9.7% | 64.6% |
| 营业利润率 | -10785.8% | -43.0% |
| 净利率 | -10223.7% | -45.7% |
| 营收同比 | 80.6% | 39.4% |
| 净利润同比 | 5.0% | -15.8% |
| 每股收益（稀释后） | $1.39 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONGH
| Q4 25 | $18.5K | $281.3M | ||
| Q3 25 | $18.9K | $265.2M | ||
| Q2 25 | $19.3K | $232.1M | ||
| Q1 25 | $19.0K | $203.5M | ||
| Q4 24 | $10.2K | $201.8M | ||
| Q3 24 | $14.4K | $191.5M | ||
| Q2 24 | $11.0K | $177.2M | ||
| Q1 24 | $10.1K | $168.5M |
净利润ACONGH
| Q4 25 | $-1.9M | $-128.5M | ||
| Q3 25 | $-1.7M | $-92.7M | ||
| Q2 25 | $-1.6M | $-99.9M | ||
| Q1 25 | $-2.0M | $-95.2M | ||
| Q4 24 | $-2.0M | $-111.0M | ||
| Q3 24 | $-1.4M | $-107.8M | ||
| Q2 24 | $-1.2M | $-102.6M | ||
| Q1 24 | $-2.4M | $-115.0M |
毛利率ACONGH
| Q4 25 | 9.7% | 64.6% | ||
| Q3 25 | 23.2% | 64.7% | ||
| Q2 25 | 26.6% | 65.0% | ||
| Q1 25 | -23.6% | 63.3% | ||
| Q4 24 | -100.9% | 61.6% | ||
| Q3 24 | -48.1% | 61.1% | ||
| Q2 24 | -112.3% | 59.1% | ||
| Q1 24 | -92.6% | 61.2% |
营业利润率ACONGH
| Q4 25 | -10785.8% | -43.0% | ||
| Q3 25 | -9666.2% | -37.3% | ||
| Q2 25 | -8988.6% | -45.9% | ||
| Q1 25 | -7856.0% | -54.6% | ||
| Q4 24 | -17652.7% | -62.4% | ||
| Q3 24 | -8995.3% | -61.3% | ||
| Q2 24 | -10350.6% | -56.8% | ||
| Q1 24 | -12609.3% | -59.2% |
净利率ACONGH
| Q4 25 | -10223.7% | -45.7% | ||
| Q3 25 | -9008.0% | -35.0% | ||
| Q2 25 | -8285.9% | -43.0% | ||
| Q1 25 | -10728.4% | -46.8% | ||
| Q4 24 | -19444.6% | -55.0% | ||
| Q3 24 | -9482.7% | -56.3% | ||
| Q2 24 | -11285.0% | -57.9% | ||
| Q1 24 | -23720.6% | -68.2% |
每股收益（稀释后）ACONGH
| Q4 25 | $1.39 | $-1.01 | ||
| Q3 25 | $-2.93 | $-0.74 | ||
| Q2 25 | $-2.75 | $-0.80 | ||
| Q1 25 | $-9.32 | $-0.77 | ||
| Q4 24 | $-809.36 | $-0.90 | ||
| Q3 24 | $-1321.49 | $-0.88 | ||
| Q2 24 | $-1362.83 | $-0.84 | ||
| Q1 24 | $-3985.22 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $378.2M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $12.8M | $-99.3M |
| 总资产 | $13.7M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONGH
| Q4 25 | $12.0M | $378.2M | ||
| Q3 25 | $11.3M | $580.0M | ||
| Q2 25 | $12.8M | $629.1M | ||
| Q1 25 | $14.8M | $698.6M | ||
| Q4 24 | $453.7K | $525.5M | ||
| Q3 24 | $1.3M | $585.0M | ||
| Q2 24 | $1.2M | $933.7M | ||
| Q1 24 | $2.1M | $1.0B |
总债务ACONGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACONGH
| Q4 25 | $12.8M | $-99.3M | ||
| Q3 25 | $12.5M | $-354.5M | ||
| Q2 25 | $14.2M | $-305.5M | ||
| Q1 25 | $15.8M | $-250.8M | ||
| Q4 24 | $970.1K | $-139.6M | ||
| Q3 24 | $2.5M | $-60.1M | ||
| Q2 24 | $1.6M | $-1.6M | ||
| Q1 24 | $2.5M | $68.3M |
总资产ACONGH
| Q4 25 | $13.7M | $2.0B | ||
| Q3 25 | $13.2M | $1.3B | ||
| Q2 25 | $14.8M | $1.3B | ||
| Q1 25 | $16.5M | $1.3B | ||
| Q4 24 | $2.1M | $1.5B | ||
| Q3 24 | $3.2M | $1.5B | ||
| Q2 24 | $3.1M | $1.6B | ||
| Q1 24 | $3.7M | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-54.2M |
| 自由现金流率自由现金流/营收 | — | -19.3% |
| 资本支出强度资本支出/营收 | — | 9.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流ACONGH
| Q4 25 | $-1.6M | $-26.4M | ||
| Q3 25 | $-1.2M | $-35.4M | ||
| Q2 25 | $-1.9M | $-60.3M | ||
| Q1 25 | $-2.5M | $-62.7M | ||
| Q4 24 | $-922.9K | $-64.5M | ||
| Q3 24 | $-1.1M | $-51.1M | ||
| Q2 24 | $-1.1M | $-94.0M | ||
| Q1 24 | $-2.2M | $-30.3M |
自由现金流ACONGH
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $-1.2M | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
自由现金流率ACONGH
| Q4 25 | — | -19.3% | ||
| Q3 25 | -6164.6% | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
资本支出强度ACONGH
| Q4 25 | — | 9.9% | ||
| Q3 25 | 38.6% | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | 0.0% | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
